CAJ | 학술논문

目的探讨肿瘤浸润性淋巴细胞(TIL)对原发性肝癌(HCC)患者术后细胞免疫功能的影响和临床疗效及半乳糖抗CD3单克隆抗体-TIL复合物（Gal-Anti-CD3-McAb-TIL)体外及体内的趋肝性。方法 (1)对30例HCC患者术后进行了TIL和重组白介素-2(rIL-2)治疗。(2)制备半乳糖基抗CD3单克隆抗体-TIL（McAb-TIL）复合物。将TIL和McAb-TIL分别与小鼠肝细胞置CO2孵箱中孵育，用倒置相差显微镜观察其趋肝性。将125I-TIL和125I-McAb-TIL分别经小鼠尾静脉注入，观察示踪剂在脏器中的分布。结果 TIL治疗后，30例患者外周血rIL-2、T细胞亚群均有上升。24例肝癌根治性切除术患者随访6～48个月无复发。McAb-TIL与肝细胞有明显粘附，给小鼠静脉注射后，TIL和McAb-TIL主要在肺中积聚，在肝内浓度较低。结论 TIL治疗可能提高HCC患者术后抗肿瘤细胞免疫功能。TIL与半乳糖抗CD3单克隆抗体结合物体内肝靶向性不明显。
목적 탐토종류침윤성림파세포(TIL)대원발성간암(HCC)환자술후세포면역공능적영향화림상료효급반유당항CD3단극륭항체-TIL복합물（Gal-Anti-CD3-McAb-TIL)체외급체내적추간성。방법 (1)대30례HCC환자술후진행료TIL화중조백개소-2(rIL-2)치료。(2)제비반유당기항CD3단극륭항체-TIL（McAb-TIL）복합물。장TIL화McAb-TIL분별여소서간세포치CO2부상중부육，용도치상차현미경관찰기추간성。장125I-TIL화125I-McAb-TIL분별경소서미정맥주입，관찰시종제재장기중적분포。결과 TIL치료후，30례환자외주혈rIL-2、T세포아군균유상승。24례간암근치성절제술환자수방6～48개월무복발。McAb-TIL여간세포유명현점부，급소서정맥주사후，TIL화McAb-TIL주요재폐중적취，재간내농도교저。결론 TIL치료가능제고HCC환자술후항종류세포면역공능。TIL여반유당항CD3단극륭항체결합물체내간파향성불명현。
Objective To evaluate the effect of TILs treatme nt onpostoperative patients with hepatocellular carcinoma (HCC) and the in vitr o and in vivo hepatic targeting tendency of a compound of Galactosyl-Anti-CD 3McAb-TILs. Methods Thirty posto perative HCC patients were treated with TILs plus rIL-2. A hepatic targeting ca rrier, Galactosyl-Anti-mouse-CD3-monoclonal antibody (Gal-Anti-CD3-McAb), was synthesized. Result I t was found that the peripheral blood level of IL-2 and T cell subset increased in all the 30 patients treated by TILs.24 HCC cases undergoing hepatectomy were treated by TILs therapy, and follow-up of 6 to 48 months found no recurrence. I n an murine experiment a combination of TIL & Galactosyl-Anti-CD3McAb-TI L tended to aggregate in lung while infused from peripheral vein. Its hepatic ta rgeting tendency was unremarkable. Conclusion Postoperative use of TILs increased patients’ antitumor immunity, p rolongs the survival, while galactosyl-anti-CD3McAb-TIL does not show a satisfactory hepatic target tendency.